A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma

33Citations
Citations of this article
66Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Polatuzumab vedotin (pola) is a CD79b-targeted antibody-drug conjugate delivering a potent antimitotic agent (monomethyl auristatin E) to B cells. This was an open-label, single-arm study of pola 1.8 mg/kg, bendamustine 90 mg/m2, rituximab 375 mg/m2 (pola + BR) Q3W for up to six cycles in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received ≥1 prior line of therapy and were ineligible for autologous stem cell transplantation (ASCT) or experienced treatment failure with prior ASCT. Primary endpoint was complete response rate (CRR) at the end of the treatment (EOT) by positron emission tomography–computed tomography (PET-CT) using modified Lugano Response Criteria. Secondary endpoints included efficacy, safety, and pharmacokinetics. Thirty-five patients (median age 71 [range 46-86] years) were enrolled. Twenty-three (66%) patients had refractory disease, and 23 (66%) had ≥2 prior lines of therapy. At a median follow-up of 5.4 (0.7-11.9) months, patients received a median of five treatment cycles. CRR was 34.3% (95% confidence interval [CI] 19.1-52.2) at EOT. Overall response rate was 42.9% at EOT, and median progression-free survival was 5.2 months (95% CI 3.6-not evaluable). Median overall survival was not reached. No fatal adverse events (AEs) were observed. Grade 3-4 AEs were mainly hematological: anemia (37%), neutropenia (31%), white blood cell count decreased (23%), thrombocytopenia/platelet count decreased/neutrophil count decreased (20% each), and febrile neutropenia (11%). Grade 1-2 peripheral neuropathy (PN; sensory and/or motor) was reported in 14% of patients; there were no ≥grade 3 PN events. This study (JapicCTI-184048) demonstrated the efficacy and safety of pola + BR in Japanese patients with R/R DLBCL who were ineligible for ASCT.

References Powered by Scopus

Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: The lugano classification

4074Citations
N/AReaders
Get full text

A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma

2320Citations
N/AReaders
Get full text

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

1033Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability

124Citations
N/AReaders
Get full text

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial

24Citations
N/AReaders
Get full text

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

14Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Terui, Y., Rai, S., Izutsu, K., Yamaguchi, M., Takizawa, J., Kuroda, J., … Shibayama, H. (2021). A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma. Cancer Science, 112(7), 2845–2854. https://doi.org/10.1111/cas.14937

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 11

52%

Researcher 8

38%

Professor / Associate Prof. 2

10%

Readers' Discipline

Tooltip

Medicine and Dentistry 20

80%

Pharmacology, Toxicology and Pharmaceut... 2

8%

Biochemistry, Genetics and Molecular Bi... 2

8%

Nursing and Health Professions 1

4%

Save time finding and organizing research with Mendeley

Sign up for free